 |
245 Diseases |  |
57 Trials |
|
57 Trials |  |
1427 News |  |
| «12...9101112131415161718192021» |
- | Trial primary completion date, Gene therapy: Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma (clinicaltrials.gov) - Aug 22, 2017
P=N/A, N=10, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Jul 2017 --> Jul 2018
- | carmustine / Generic mfg.
Biomarker, Journal: Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma. (Pubmed Central) - Aug 20, 2017
Conclusion 2HG concentration as measured by MRS was reproducible and reliably reflected the disease state. These data provide a basis for incorporating 2HG MRS into clinical management of IDH-mutated gliomas.
- | 90Y-BC8-DOTA / Fred Hutchinson Cancer Center
Enrollment closed, Enrollment change, Trial primary completion date: Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies (clinicaltrials.gov) - Aug 9, 2017
P1/2, N=21, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
These data provide a basis for incorporating 2HG MRS into clinical management of IDH-mutated gliomas. Recruiting --> Active, not recruiting | N=44 --> 21 | Trial primary completion date: Sep 2018 --> Dec 2017
- | melphalan / Generic mfg., cytarabine / Generic mfg.
Journal: Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the (BMT CTN) 0803/(AMC) 071 Trial. (Pubmed Central) - Aug 3, 2017
P2
HRL patients should be considered candidates for AHCT if they meet standard transplant criteria. The trial is registered to www.clinicaltrials.gov as NCT01141712.
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Aug 3, 2017
P1, N=15, Recruiting, Sponsor: Washington University School of Medicine
The trial is registered to www.clinicaltrials.gov as NCT01141712. Not yet recruiting --> Recruiting
- | cyclophosphamide / Generic mfg., etoposide IV / Generic mfg., carmustine / Generic mfg.
Trial primary completion date: Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma (clinicaltrials.gov) - Jul 28, 2017
P=N/A, N=25, Active, not recruiting, Sponsor: City of Hope Medical Center
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2017 --> Oct 2018
- | Trial completion: Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma (clinicaltrials.gov) - Jul 21, 2017
P2, N=50, Completed, Sponsor: Washington University School of Medicine
Trial primary completion date: Oct 2017 --> Oct 2018 Active, not recruiting --> Completed
- | Starasid (cytarabine ocfosfate) / Nippon Kayaku
Trial suspension, Gene therapy: Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant (clinicaltrials.gov) - Jul 18, 2017
P1/2, N=18, Suspended, Sponsor: AIDS Malignancy Consortium
Active, not recruiting --> Completed Recruiting --> Suspended
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
New P2 trial: EATL-001: CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1. (clinicaltrials.gov) - Jul 13, 2017
P2, N=25, Not yet recruiting, Sponsor: Imagine Institute
- | Trial primary completion date, Metastases: Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov) - Jul 6, 2017
P2, N=20, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Trial primary completion date: Jun 2017 --> Jun 2018
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Preclinical, Trial initiation date, Trial primary completion date: Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jul 5, 2017
P2, N=40, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2017 --> Jun 2018 Initiation date: Jun 2017 --> Sep 2017 | Trial primary completion date: Jun 2020 --> Sep 2020
- | carmustine / Generic mfg.
Journal: Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial. (Pubmed Central) - Jul 1, 2017
P1/2
The MTD for dual-dose O6-benzylguanine plus carmustine was also ascertained. Trial Registration clinicaltrials.gov Identifier: NCT00961220.
- | mycophenolate mofetil / Generic mfg., sirolimus / Generic mfg.
Trial initiation date, Trial primary completion date: Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT (clinicaltrials.gov) - Jun 5, 2017
P2, N=3, Terminated, Sponsor: Stanford University
Trial Registration clinicaltrials.gov Identifier: NCT00961220. Initiation date: Sep 2009 --> Aug 2006 | Trial primary completion date: May 2011 --> Aug 2010
- | carmustine / Generic mfg.
Journal: A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. (Pubmed Central) - Jun 2, 2017
RT was associated with improved LC of high-risk localized disease and was well tolerated with modern techniques. Cancer 2017;123:1363-1371.
- | Depocyte (liposomal cytarabine) / Mundipharma, Leadiant Biosci, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment open: Auto Stem Cell Transplant for Lymphoma Patients (clinicaltrials.gov) - May 23, 2017
P2, N=150, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Cancer 2017;123:1363-1371. Not yet recruiting --> Recruiting
- | Trial completion, Trial primary completion date: Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma (clinicaltrials.gov) - May 4, 2017
P1, N=34, Completed, Sponsor: University of Nebraska
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Aug 2015 --> Nov 2014
- | Enrollment closed: CALGB 51101: Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma (clinicaltrials.gov) - May 3, 2017
P2, N=113, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | Trial primary completion date: Aug 2015 --> Nov 2014 Recruiting --> Active, not recruiting
- | Enrollment closed, Enrollment change: Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma (clinicaltrials.gov) - May 3, 2017
P2, N=421, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=325 --> 421
- | vadacabtagene leraleucel (JCAR015) / BMS
Trial primary completion date: High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Apr 27, 2017
P1, N=17, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting | N=325 --> 421 Trial primary completion date: Apr 2017 --> Apr 2018
- | Depocyte (liposomal cytarabine) / Mundipharma, Leadiant Biosci, Neupogen (filgrastim) / Kyowa Kirin, Amgen
New P2 trial: Auto Stem Cell Transplant for Lymphoma Patients (clinicaltrials.gov) - Apr 24, 2017
P2, N=150, Not yet recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
- || Trial primary completion date: Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov) - Apr 10, 2017
P2, N=150, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Apr 2017 --> Apr 2018 Trial primary completion date: Oct 2017 --> Oct 2018
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Metastases: Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - Mar 30, 2017
P2, N=45, Completed, Sponsor: University of Maryland
Trial primary completion date: Oct 2017 --> Oct 2018 Active, not recruiting --> Completed
- | Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial completion, Trial primary completion date, Combination therapy: Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 29, 2017
P2, N=118, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Mar 2018 --> Mar 2017 | Active, not recruiting --> Completed | Trial primary completion date: Mar 2018 --> Mar 2017
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Preclinical, Trial initiation date, Trial primary completion date: Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 22, 2017
P2, N=40, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Mar 2018 --> Mar 2017 | Active, not recruiting --> Completed | Trial primary completion date: Mar 2018 --> Mar 2017 Initiation date: Mar 2017 --> Jun 2017 | Trial primary completion date: Mar 2020 --> Jun 2020
- | lomustine / Generic mfg., carmustine / Generic mfg.
Journal: Analysis of Risk Factors for Abnormal Pulmonary Function in Pediatric Cancer Survivors. (Pubmed Central) - Mar 19, 2017
Almost two-thirds of survivors screened per the COG-LTFU Guidelines had an abnormal PFT but a majority reported no clinical symptoms. Hyperinflation was the most prevalent abnormality.
- | Blincyto (blinatumomab) / Astellas, Amgen
New P1 trial: Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov) - Mar 7, 2017
P1, N=15, Not yet recruiting, Sponsor: Washington University School of Medicine
- | bendamustine / Generic mfg.
Trial initiation date, Trial primary completion date: Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma (clinicaltrials.gov) - Mar 3, 2017
P=N/A, N=30, Recruiting, Sponsor: Weill Medical College of Cornell University
Hyperinflation was the most prevalent abnormality. Initiation date: Feb 2014 --> Jun 2014 | Trial primary completion date: Feb 2016 --> Jun 2017
- | Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial primary completion date: Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation (clinicaltrials.gov) - Feb 23, 2017
P2, N=50, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Feb 2014 --> Jun 2014 | Trial primary completion date: Feb 2016 --> Jun 2017 Trial primary completion date: Nov 2017 --> Nov 2018
- | Starasid (cytarabine ocfosfate) / Nippon Kayaku
Enrollment open, Trial primary completion date: Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies (clinicaltrials.gov) - Feb 20, 2017
P1, N=44, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Nov 2017 --> Nov 2018 Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2019 --> Mar 2021
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (clinicaltrials.gov) - Feb 12, 2017
P2, N=40, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2019 --> Mar 2021 Trial primary completion date: Jun 2017 --> Dec 2017
- temozolomide / Generic mfg.
Phase classification: DRBEAT: The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma (clinicaltrials.gov) - Feb 2, 2017
P2a, N=20, Recruiting, Sponsor: Cedars-Sinai Medical Center
Trial primary completion date: Jun 2017 --> Dec 2017 Phase classification: P2 --> P2a
- Enrollment change: CALGB 51101: Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma (clinicaltrials.gov) - Feb 2, 2017
P2, N=110, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Phase classification: P2 --> P2a N=160 --> 110
- Avastin (bevacizumab) / Roche
Enrollment change, Trial withdrawal, Trial primary completion date: NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse (clinicaltrials.gov) - Feb 2, 2017
P2, N=0, Withdrawn, Sponsor: University of California, Davis
N=160 --> 110 N=20 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Jan 2017
- Rituxan (rituximab) / Roche
Trial primary completion date: IELSG32: Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (clinicaltrials.gov) - Jan 24, 2017
P2, N=126, Active, not recruiting, Sponsor: International Extranodal Lymphoma Study Group (IELSG)
N=20 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Jan 2017 Trial primary completion date: Dec 2016 --> Mar 2017
- || Trial primary completion date: PRECIS: Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients (clinicaltrials.gov) - Jan 24, 2017
P2, N=140, Active, not recruiting, Sponsor: Institut Curie
Trial primary completion date: Dec 2016 --> Mar 2017 Trial primary completion date: Feb 2017 --> Aug 2017
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P2 trial, Preclinical: Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jan 12, 2017
P2, N=40, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- Phase classification, Post-transplantation: Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies (clinicaltrials.gov) - Jan 11, 2017
P1, N=22, Completed, Sponsor: Sally Arai
Trial primary completion date: Feb 2017 --> Aug 2017 Phase classification: P1/2 --> P1
- Istodax (romidepsin) / Astellas, BMS
Trial primary completion date: A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jan 6, 2017
P2, N=33, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Phase classification: P1/2 --> P1 Trial primary completion date: Jul 2017 --> Jul 2018
- Starasid (cytarabine ocfosfate) / Nippon Kayaku
Trial initiation date: Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies (clinicaltrials.gov) - Dec 15, 2016
P1, N=44, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Jul 2017 --> Jul 2018 Initiation date: Sep 2016 --> Feb 2017
- irinotecan / Generic mfg.
Trial primary completion date: Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme (clinicaltrials.gov) - Dec 7, 2016
P2, N=58, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Initiation date: Sep 2016 --> Feb 2017 Trial primary completion date: Jul 2009 --> Oct 2006
- etoposide oral / Generic mfg., cisplatin / Generic mfg.
Trial primary completion date: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Dec 7, 2016
P2, N=93, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Jul 2009 --> Oct 2006 Trial primary completion date: May 2008 --> Aug 2001
- | irinotecan / Generic mfg.
Trial completion: Irinotecan Plus Radiation Therapy Followed By Chemotherapy in Treating Patients With Glioblastoma Multiforme (clinicaltrials.gov) - Dec 6, 2016
P2, N=58, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: May 2008 --> Aug 2001 Active, not recruiting --> Completed
- | etoposide oral / Generic mfg., cisplatin / Generic mfg.
Trial completion: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Dec 6, 2016
P2, N=93, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Trial primary completion date: PRECIS: Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients (clinicaltrials.gov) - Nov 21, 2016
P2, N=140, Active, not recruiting, Sponsor: Institut Curie
Active, not recruiting --> Completed Trial primary completion date: Oct 2014 --> Feb 2017
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial primary completion date: High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study (clinicaltrials.gov) - Nov 14, 2016
P2, N=25, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Oct 2014 --> Feb 2017 Trial primary completion date: Jul 2015 --> Nov 2015
- Trial primary completion date: High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors (clinicaltrials.gov) - Nov 9, 2016
P=N/A, N=174, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Jul 2015 --> Nov 2015 Trial primary completion date: Oct 2016 --> Apr 2018
- Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial primary completion date: Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Oct 17, 2016
P2, N=44, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Oct 2016 --> Apr 2018 Trial primary completion date: Jan 2015 --> Apr 2017
- Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Enrollment change, Trial termination, Trial primary completion date: SPINOZA: BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin (clinicaltrials.gov) - Oct 11, 2016
P3, N=3, Terminated, Sponsor: City of Hope Medical Center
Trial primary completion date: Jan 2015 --> Apr 2017 N=158 --> 3 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Oct 2016; Withdrawal of sponsor support
- | Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment open, IO biomarker: Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Sep 26, 2016
P3, N=302, Recruiting, Sponsor: National Cancer Institute (NCI)
N=158 --> 3 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Oct 2016; Withdrawal of sponsor support Not yet recruiting --> Recruiting
- | cyclophosphamide / Generic mfg., carmustine / Generic mfg.
Enrollment closed, Trial primary completion date: Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 23, 2016
P3, N=360, Active, not recruiting, Sponsor: Vastra Gotaland Region
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Jul 2017